Posted by Michael Wonder on 24 Jun 2022
Health Canada expands approval of Enhertu for adults with HER2 positive metastatic breast cancer
23 June 2022 - Approval based on the ground-breaking DESTINY-Breast03 Phase 3 trial, showing Enhertu reduced the risk of disease progression or death by 72 per cent compared to standard of care.
Health Canada approved Enhertu (trastuzumab deruxtecan) for the treatment of adult patients with unresectable or metastatic human epidermal growth factor receptor 2 positive breast cancer who have received at least one prior anti-HER2 based regimen either in the metastatic setting, or in the neo-adjuvant or adjuvant setting and developed disease recurrence during or within six months of completing neo-adjuvant or adjuvant therapy.
